Half a century of advancements in biomedical science paved the way for today’s powerful weight-loss drugs like Ozempic — so ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

HashiCorp (HCP) edged lower by 0.3% amid some concern that its planned sale to IBM (IBM) may be pushed into next year due to ...

Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

EMA endorses Novo Nordisk's Wegovy for treating heart failure and lowering heart risks in obese patients. Second approval ...

Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...